An international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5 gels [Indevus Pharmaceuticals] for the prevention of vaginally acquired HIV infection.

Trial Profile

An international multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5 gels [Indevus Pharmaceuticals] for the prevention of vaginally acquired HIV infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2017

At a glance

  • Drugs PRO 2000 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Endo Pharmaceuticals Solutions
  • Most Recent Events

    • 20 Sep 2010 Results have been reported in the September 20, 2010 online issue of the Lancet.
    • 16 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections.
    • 14 Dec 2009 The results of this trial were announced by AVAC in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top